Table 7 Incremental cost-effectiveness ratio of PHiD-CV vs. PCV13 vaccination programs
|  | PCV13 (A) | PHiD-CV (B) | Difference (B−A) |
|---|---|---|---|
Total discounted costs (NTD) | 1 392 017 676 | 1 383 217 323 | -8 800 353 |
Total discounted QALYs gained | 1 799 828 | 1 799 849 | 21 |
Incremental cost-effectiveness ratio | Dominant (cost saving) | ||